HERALD

MCAZ EXPERTS: AFRICA MEDICINES AGENCY APPOINTMENT SUPPLEMENT

Features Writer

A proud moment for Zimbabwe’s medicines regulatory sector has seen three experts from the Medicines Control Authority of Zimbabwe (MCAZ) appointed to leadership positions in the inaugural technical committees of the African Medicines Agency (AMA), marking an important recognition of the country’s growing contribution to medicines regulation across the continent.

With two officers appointed as committee chairpersons and another as vice chairperson, the appointments highlight the depth of scientific and regulatory expertise developed within Zimbabwe’s national medicines regulator.

They also present an opportunity for the country’s professionals to contribute to a stronger, more coordinated African regulatory environment, ultimately supporting access to safe, effective and quality-assured medical products.

The appointments were announced following the inauguration of the Agency’s seven technical committees in Kigali, Rwanda, on October 26, 2026.

Mrs Caroline Gertrude Dandira-Samatanga, head of MCAZ’s licensing and enforcement division, has been appointed vice chairperson of the Technical Committee on Regulatory Inspections.

Ms Grace Ruramai Matimba, chief regulatory officer in the evaluations and registrations division, will chair the technical committee on evaluation of medicines, Vaccines and Biologicals. Mr Tatenda Nyamandi, senior regulatory officer in the pharmacovigilance division, will chair the technical committee on vigilance.

These committees address questions that affect patients directly: whether manufacturing and clinical research meet appropriate standards, whether the evidence supports the quality, safety and effectiveness of medicines, and whether safety concerns are detected and addressed as products are used.

Leadership roles across three of the seven committees reflect the breadth of expertise within MCAZ. They also place significant responsibility on the appointed experts to contribute independent, evidence-based scientific advice.

The African Medicines Agency (AMA) is a specialised agency of the African Union, established under a treaty adopted in 2019 and headquartered in Kigali. It works to strengthen the capacity of countries and regional bodies to regulate medical products and improve access to safe, effective and quality-assured products.

Its technical committees bring together expertise to support scientific assessments, inspections and regulatory cooperation. AMA complements the work of national regulators while national authorities retain their statutory responsibilities.

For patients, the value of this cooperation lies in what regulators can achieve together. Sharing scientific expertise and making appropriate use of one another’s work can reduce unnecessary duplication and help authorities use limited resources more effectively.

Cooperation can also support a more coordinated response to substandard and falsified medical products and emerging safety concerns. These are practical objectives to which the three MCAZ experts will contribute through their committee responsibilities.

Established under the Medicines and Allied Substances Control Act (Chapter 15:03), MCAZ protects public and animal health through the regulation of medicines and allied substances in Zimbabwe.

The appointments build on sustained investment in its scientific capacity and regulatory systems, including work undertaken through the World Health Organisation’s Global Benchmarking Tool. That progress reflects the contribution of evaluators, inspectors, laboratory analysts, pharmacovigilance practitioners and support teams across the Authority.

MCAZ’s record shows consistent alignment with the National Development Strategy 2 (NDS2) for 2026 to 2030. Having met international regulatory standards and achieved 100 percent compliance with the WHO Global Benchmarking Tool, the authority has advanced the strategy’s health and well-being outcome by safeguarding the safety, quality and efficacy of medicines in circulation, acting against substandard, falsified and illegally manufactured products, and supporting local pharmaceutical manufacturing through predictable, transparent and science-based regulatory processes.

The appointment of three of its officers to leadership roles in AMA’s technical committees shows that this approach is recognised beyond Zimbabwe’s borders.

The officers will serve as independent scientific experts, rather than as representatives of MCAZ or Zimbabwe. Their work will be governed by AMA’s requirements on confidentiality and conflicts of interest.

National pride in their appointments rest on their professional achievements and the institution that helped develop their expertise. Respect for their independence is essential to the credibility of the scientific advice they provide.

MCAZ brings longstanding experience of regional regulatory cooperation. It is a founding participant and the implementing agency for ZAZIBONA, the collaborative medicines registration initiative established in 2013 by Zambia, Zimbabwe, Botswana and Namibia.

Through joint assessments and cooperation on good manufacturing practice inspections, the initiative enables participating authorities to share expertise and regulatory work while retaining responsibility for national decisions. It has since expanded to involve other countries in the Southern African Development Community.

This experience is relevant to AMA’s continental ambitions. Effective cooperation requires more than common procedures. Regulators must develop trust in one another’s assessments, apply consistent scientific standards and exchange information responsibly.

MCAZ’s participation in ZAZIBONA has provided practical experience of these demands, offering a foundation on which its experts can draw as they contribute to the work of AMA.

For Zimbabwe, the appointments demonstrate the value of sustained investment in specialised scientific and technical skills.

They create opportunities for professional exchange and contributions to regulatory approaches that can benefit public health across Africa. Knowledge gained through this work may also support institutional learning at MCAZ, subject to confidentiality requirements.

The value of such engagement will depend on how effectively it supports sound regulatory practice and the protection of patients.

The recognition also brings a responsibility to sustain performance at home. MCAZ must continue to invest in its people, strengthen its systems and uphold transparency, accountability and continuous improvement.

Continental engagement should reinforce that commitment. Maintaining a capable national regulator remains essential to public confidence in medicines and to an environment in which responsible pharmaceutical manufacturers can meet clear and consistently applied standards.

The appointments of Mrs Dandira-Samatanga, Ms Matimba and Mr Nyamandi are a source of pride for MCAZ and Zimbabwe. They recognise the achievements of the three experts and the collective work of the Authority’s staff.

As AMA develops its scientific capabilities, their contribution will form part of a wider African effort to strengthen medicines regulation and support equitable access to quality-assured medical products.

The lasting value of this recognition will lie in its contribution to stronger regulatory cooperation and better protection of patients across Africa.

Leave a Comment